Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Net Cash Flow (2022 - 2025)

Historic Net Cash Flow for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to $6.9 million.

  • bioAffinity Technologies' Net Cash Flow rose 1545033.87% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year increase of 28420.59%. This contributed to the annual value of -$1.7 million for FY2024, which is 8002.51% up from last year.
  • Latest data reveals that bioAffinity Technologies reported Net Cash Flow of $6.9 million as of Q3 2025, which was up 1545033.87% from $358129.0 recorded in Q2 2025.
  • bioAffinity Technologies' Net Cash Flow's 5-year high stood at $13.3 million during Q3 2022, with a 5-year trough of -$3.8 million in Q3 2023.
  • For the 4-year period, bioAffinity Technologies' Net Cash Flow averaged around $435236.3, with its median value being -$660585.0 (2025).
  • Per our database at Business Quant, bioAffinity Technologies' Net Cash Flow tumbled by 39448.32% in 2023 and then soared by 1545033.87% in 2025.
  • bioAffinity Technologies' Net Cash Flow (Quarter) stood at -$1.9 million in 2022, then grew by 9.47% to -$1.7 million in 2023, then skyrocketed by 120.66% to $348711.0 in 2024, then soared by 1869.07% to $6.9 million in 2025.
  • Its Net Cash Flow was $6.9 million in Q3 2025, compared to $358129.0 in Q2 2025 and -$660585.0 in Q1 2025.